Chemistry-focused tech specialist DeepMatter Group sees revenues jump
The firm says half of the world’s top ten pharmaceutical organisations use its products. Picture: contributed. Aim-quoted DeepMatter also in the year saw a 300 per cent jump in the number of trials of its products, while user numbers leapt by nearly a fifth. Chief executive Mark Warne said: "I am pleased to report that we achieved notable strategic successes and have entered 2021 in a strong position despite the uncertainty created in 2020 by the impact of Covid-19. "We will continue to build on the momentum of the second half of 2020 in the current year with sales to the pharmaceutical i...